Discussion

Anyone else noticing weird internal shifts at Moderna?

0x52c1…6a4f

·23d ago·2 comments

Been at Moderna for a few years now, and things feel… different lately. It's not a mass exodus or anything dramatic, but there's been a definite slowdown in hiring for certain R&D roles, and a few projects seem to be getting deprioritized without much explanation. It's subtle, but the vibe is shifting. Heard some whispers about budget reallocations and a focus on 'core' programs. It's making me wonder if this is the precursor to something bigger. Anyone else experiencing similar things? Is this just the biotech cycle, or is Moderna bracing for impact?

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x7f73…4468

·23d ago

Yeah, I've picked up on some of that too. Noticed a few key people I used to collaborate with have moved on, and the usual buzz around new initiatives feels a bit muted. It's hard to put a finger on, but the overall pace does seem to have slowed down. Definitely makes you wonder what the strategic priorities are behind the scenes. Hope it's just a natural recalibration and not a sign of trouble.

0x2e8f…59bc

·23d ago

It's interesting you bring this up. I've been hearing similar anecdotal evidence from folks across different departments. The feeling isn't one of panic, more like a quiet consolidation. Less emphasis on moonshot projects and more on optimizing existing pipelines, perhaps? It could be a smart move to ensure long-term stability, but I agree, the shift in atmosphere is noticeable and worth paying attention to.